Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
The goal of this observational and interventional study is to understand how therapeutic deep brain stimulation (DBS) affects attention, perception and cognition in participants with Parkinson's disease (PD) and essential tremor (ET). The main questions it aims to answer are:
Using an eye tracking camera, investigators will study how participants with PD and ET look at and perceive facial expressions of emotion before and after starting DBS therapy, in comparison to a group of healthy participants without ET, PD or DBS. Participants with PD and ET will see and rate morphed facial expressions on a computer screen in three conditions:
Full description
Parkinson's disease (PD) is the second most common age-related neurodegenerative disorder, with approximately 90,000 new cases diagnosed annually in North America. Although motor symptoms define the disorder, PD also leads to cognitive and emotional changes, such as difficulties in recognizing facial expressions and regulating attention, which often overshadow motor issues as the disease progresses. The goal of this study is to better understand the link between attention, eye movement, and emotional perception in PD, testing the hypothesis that disrupted attention leads to altered perception of facial emotions. The study will also investigate how deep brain stimulation (DBS) of the subthalamic nucleus (STN) affects these processes, providing critical insights into the cognitive and perceptual consequences of the treatment.
This research addresses a critical gap in understanding non-motor symptoms of Parkinson's disease by exploring how attention, eye movement, and perception interact. Findings will provide evidence on whether cognitive and emotional symptoms in PD stem from impaired attentional control, offering a new framework for treating these deficits. Additionally, the study will shed light on how different DBS frequencies affect perception and cognition, potentially guiding personalized stimulation strategies to alleviate both motor and non-motor symptoms. The insights gained may influence future therapies for PD, advancing both scientific knowledge and patient care.
Participants will be divided into three groups: PD undergoing DBS, essential tremor (ET) undergoing DBS (as a comparison group for non-PD DBS effects) and healthy age- and sex-matched controls. Participants will complete facial morph rating tasks (rating faces as happy, neutral, or sad) and visual search tasks (finding faces among distractors), while their eye movements are tracked.
The first study aim is to measure how altered attention influences facial emotion perception in PD by tracking eye movements while participants view and categorize emotional face stimuli. The second aim is to characterize brain activity in the STN related to attentional and perceptual processes during awake DBS surgery by capturing microelectrode recordings (MER) of neural activity while participants view emotional faces, allowing researchers to map STN's role in guiding attention and eye movements. The third aim is to test how DBS stimulation at different frequencies (high, low, or off) affects attention, eye movement, and emotional perception by having participants perform visual and perceptual tasks under varying DBS settings to evaluate how brain stimulation influences cognitive and perceptual functions.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
All Participants (Aim 1):
DBS Participants (Aim 1):
Comparison Participants (Aim 1):
o Selection by age matching to participants in PD group
Parkinson's disease (PD) and essential tremor (ET) Participants (Aim 2):
Parkinson's disease (PD) and essential tremor (ET) Participants (Aim 3):
Exclusion Criteria
All Participants (Aim 1):
DBS Participants (Aim 1):
o Insufficient therapeutic control of motor symptoms to engage in tasks requiring button press or use of a mouse to control a slider
Healthy Comparison Participants (Aim 1):
o History of neurodegenerative disorder
Parkinson's disease (PD) and essential tremor (ET) Participants (Aim 2):
Parkinson's disease (PD) and essential tremor (ET) Participants (Aim 3):
Primary purpose
Allocation
Interventional model
Masking
138 participants in 1 patient group
Loading...
Central trial contact
Dulce Maroni, PhD; Christopher K Kovach, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal